Figure 2.
Sunitinib treatment reduces cardiac fibroblast viability. Cells were treated with sunitinib or imatinib (0.1–10 μM) in the presence of serum for 18 h. Cell proliferation was assessed via MTT assays. (A) Sunitinib treated CF (B) imatinib treated CF. Results are expressed as mean ± S.E.M and are normalized to control (n = 3, *p < 0.05).